PET/MRI in Abdominopelvic Oncology

Advantages and disadvantages of PET/MRI, as compared with those of PET/CT, are outlined, and applications of PET/MRI in abdominopelvic oncology are presented.

Course ID: Q00711 Category:
Modalities: , , ,


Satisfaction Guarantee


Targeted CE per ARRT’s Discipline, Category, and Subcategory classification:
[Note: Discipline-specific Targeted CE credits may be less than the total Category A credits approved for this course.]

Magnetic Resonance Imaging: 0.25
Procedures: 0.25
Body: 0.25

Nuclear Medicine Technology: 0.25
Procedures: 0.25
Endocrine and Oncology Procedures: 0.25

Registered Radiologist Assistant: 0.25
Procedures: 0.25
Abdominal Section: 0.25

Radiation Therapy: 0.25
Patient Care: 0.25
Patient and Medical Record Management: 0.25


  1. Introduction
  2. Technical and Workflow Considerations for PET/MRI
  3. PET/MRI versus PET/CT
  4. Pearls and Pitfalls of PET/MRI
  5. Prostate Cancer
  6. Neuroendocrine Tumors
  7. Rectal Cancer
  8. Pancreatic Cancer
  9. Hepatobiliary Cancer
  10. Gynecologic Cancers
  11. Other Tumors
  12. Conclusion


Upon completion of this course, students will:

  1. list limitations in the acquisition and interpretation of PET/CT data
  2. identify the date that PET/MRI was first approved for clinical use in the Unites States
  3. list the imaging vendors that sell commercial PET/MRI systems in the Unites States
  4. describe the hardware components of current PET/MRI systems
  5. list the tissue types that are identified by Dixon MRI sequences used for attenuation correction
  6. describe the general guidelines for PET/MRI acquisitions
  7. list practical challenges that have limited widespread adoption of PET/MRI into clinical practice
  8. list the benefits of PET/MRI over PET/CT
  9. compare the sensitivity of PET/MRI and PET/CT
  10. identify tissue types that are not accounted for by MRAC images
  11. list common causes of dephasing on MRAC images that can result in PET signal loss
  12. identify the most common noncutaneous malignancy in men
  13. describe the current NCCN imaging recommendations for patients with high-risk prostate cancer
  14. describe the physical half-life carbon-11 PET radiotracers
  15. list known limitations of PET imaging of prostate cancer using 18F fluciclovine
  16. list the tissue types in the body from which NETs most commonly arise
  17. list radiotracers that have been used for noninvasive diagnosis and staging of patients with NETs
  18. describe an abbreviated MRI protocol for hepatic metastases from NETs
  19. identify isotopes used for peptide receptor radionuclide therapy for NETs
  20. identify the most common malignancy that affects the digestive system
  21. describe the modality that is typically used to identify and diagnose rectal cancers
  22. list imaging findings that make it difficult to diagnose lymph node metastases from rectal cancer at MRI
  23. identify radiotracers that can increase reader confidence and detection of pelvic nodal metastases in patients with rectal cancer
  24. list the MRI sequences that may improve detection of hepatic metastases from rectal cancer
  25. describe the second most common malignancy of the digestive system
  26. describe the utility of FDG PET in the staging of newly diagnosed pancreatic cancer
  27. describe the standard of care treatment for patients with newly diagnosed pancreatic adenocarcinoma
  28. describe challenges affecting CT and MRI imaging following treatment for pancreatic cancer
  29. list examples of hepatobiliary cancers
  30. identify imaging modalities that form the cornerstone for hepatocellular cancer diagnosis and monitoring response to treatment
  31. identify PET radiotracers that target fibroblast activity
  32. list the most commonly diagnosed gynecologic cancers
  33. identify the best imaging modality for identifying primary gynecologic cancer tumors
  34. identify the best imaging modality for identifying gynecologic cancer lymph node metastases
  35. describe clinical symptoms that may indicate malignant transformation of neurofibromas